No connection

Search Results

OKYO vs SERA

OKYO
OKYO Pharma Limited
BEARISH
Price
$1.65
Market Cap
$86.6M
Sector
Healthcare
AI Confidence
95%
SERA
Sera Prognostics, Inc.
BEARISH
Price
$2.30
Market Cap
$90.0M
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
OKYO
--
SERA
--
Forward P/E
OKYO
-8.25
SERA
-3.36
P/B Ratio
OKYO
-18.54
SERA
1.19
P/S Ratio
OKYO
--
SERA
1111.49
EV/EBITDA
OKYO
-9.5
SERA
-1.49

Profitability

Gross Margin
OKYO
0.0%
SERA
-102.47%
Operating Margin
OKYO
0.0%
SERA
-89540.0%
Profit Margin
OKYO
0.0%
SERA
0.0%
ROE
OKYO
--
SERA
-51.83%
ROA
OKYO
-104.63%
SERA
-26.15%

Growth

Revenue Growth
OKYO
--
SERA
-58.3%
Earnings Growth
OKYO
--
SERA
--

Financial Health

Debt/Equity
OKYO
--
SERA
0.03
Current Ratio
OKYO
0.58
SERA
1.69
Quick Ratio
OKYO
0.53
SERA
1.62

Dividends

Dividend Yield
OKYO
--
SERA
--
Payout Ratio
OKYO
0.0%
SERA
0.0%

AI Verdict

OKYO BEARISH

OKYO exhibits severe financial distress, anchored by a weak Piotroski F-Score of 2/9 and a critical liquidity position. The company's negative Price/Book ratio (-18.54) and an ROA of -104.63% indicate significant insolvency risk and a lack of tangible asset backing. While analysts maintain a speculative target price of $8.00, the fundamental data reveals a company unable to cover short-term obligations (Current Ratio 0.58) with no current revenue stream. The disconnect between the bullish analyst target and the bearish deterministic health scores suggests a high-risk speculative play rather than a value investment.

Strengths
Significant upside potential if analyst target of $8.00 is realized
Positive 1-year price performance (+47.3%)
Operating in the high-growth Biotechnology sector
Risks
Severe liquidity crisis with a Current Ratio of 0.58
Negative shareholder equity as evidenced by Price/Book of -18.54
Critical financial health (Piotroski F-Score 2/9)
SERA BEARISH

SERA presents a contradictory profile with a stable Piotroski F-Score of 6/9 but catastrophic operational metrics. While the balance sheet remains lean with very low debt (D/E 0.03) and adequate liquidity, the company is experiencing a severe revenue collapse (-58.3% YoY) and negative gross margins (-102.47%), indicating that the cost of producing its services exceeds the revenue generated. The extreme Price-to-Sales ratio (1111.49) and aggressive insider selling suggest a lack of confidence in the current business model, rendering the single analyst's 'strong buy' rating highly speculative.

Strengths
Low leverage with a Debt/Equity ratio of 0.03
Stable short-term liquidity (Current Ratio 1.69)
Piotroski F-Score of 6/9 indicates stable financial health relative to its own history
Risks
Severe revenue contraction (-58.3% YoY and Q/Q)
Negative gross margins (-102.47%) indicating a non-viable cost structure
Extreme valuation relative to sales (P/S 1111.49)

Compare Another Pair

OKYO vs SERA: Head-to-Head Comparison

This page compares OKYO Pharma Limited (OKYO) and Sera Prognostics, Inc. (SERA) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile